Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corporation on April 13, 2017. The report addresses corporate governance changes involving the resignation of two directors and members of the Scientific Advisory Board.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignations: Dr. Chia Soo and Dr. Ben Wu resigned as directors and members of the Scientific Advisory Board on April 13, 2017.
- Reason for Resignation: The resignations stem from disagreements with the Company, as detailed in the attached Notice of Resignation (Exhibit 17).
- Board Composition: The Board of Directors has decided to reduce the size of the Board to five members.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary regarding future operations. The primary risk disclosed is the internal disagreement leading to the departure of key scientific advisors and directors.
Investor Verification Checklist
- Review Exhibit 17 (Notice of Resignation) to understand the specific nature of the disagreements between the departing directors and the Company.
- Verify the current composition of the Board of Directors following the reduction to five members.
- Assess the potential impact of losing two Scientific Advisory Board members on the Company's research and development pipeline.